drugset / Trial / NCT03982134
PDR001 + Panobinostat for Melanoma and NSCLC
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this research study is to find the dose of the study drug PDR001 that, when given in combination with the drug Panobinostat, results in the best outcomes for metastatic melanoma and non-small cell lung cancer (NSCLC)
Timeline
- Start
- 2019-09
- Primary completion
- 2021-05-01
- Completion
- 2022-05-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Panobinostat | Small molecule | — | — |
| Subject | Spartalizumab | Monoclonal antibody | 400 mg | — |